Jiangsu Hengrui Pharmaceuticals(600276.SH): The market approval application for HR091506 tablets has been accepted by the National Medical Products Administration.
Hengrui Medicine (600276.SH) issued an announcement that the company recently received a "Notice of Acceptance" from the National Medical Products Administration for the application of market approval for its HR091506 tablet. The proposed indication (or main function) is for the long-term treatment of hyperuricemia in patients with gout.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has recently received a "Notice of Acceptance" from the National Medical Products Administration for the application for market approval of HR091506 tablets. The proposed indication is for the long-term treatment of hyperuricemia in gout patients.
HR091506 tablets are a pulsatile-release non-bisphosphonate oral sustained-release tablet independently developed by the company using gastric retention technology. The product consists of an immediate-release part and a delayed-release part. After oral administration, the immediate-release part quickly releases in the stomach to achieve effective blood drug concentration, while the delayed-release part remains in the stomach to continuously release, aiming to prolong the effective blood drug concentration maintenance time and improve the rate of achieving the uric acid-lowering target. As of now, the total research and development investment in the HR091506 tablet project is approximately 126.7 million yuan (unaudited).
Related Articles
On February 5th, MILLIONHOPE IND (01897) spent 990 Hong Kong dollars to repurchase 2000 shares.
Tsaker Technology (01986): It is estimated that the net profit attributable to parent company of Tsaker Technology in 2025 will be approximately 146 million yuan, a year-on-year increase of 26.55%.
MARKETINGFORCE (02556) spent HK$1.4498 million to repurchase 37,600 shares on February 5th.
On February 5th, MILLIONHOPE IND (01897) spent 990 Hong Kong dollars to repurchase 2000 shares.
Tsaker Technology (01986): It is estimated that the net profit attributable to parent company of Tsaker Technology in 2025 will be approximately 146 million yuan, a year-on-year increase of 26.55%.
MARKETINGFORCE (02556) spent HK$1.4498 million to repurchase 37,600 shares on February 5th.
